Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE drug wars: Tarceva vs Iressa, Revlimid vs IFN alpha, Botox vs SoC, and others

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal institute for England and Wales, is to put Roche's Tarceva (erlotinib) under the microscope as a first-line option for treating adults with epidermal growth factor receptor (EGFR) mutation positive, locally advanced or metastatic non-small-cell lung cancer (NSCLC). The institute has recently put out for consultation a draft appraisal scope for Tarceva, as well as one for Allergan's Botox and three for Celgene's Revlimid.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts